You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 8,303,987


✉ Email this page to a colleague

« Back to Dashboard


Title:Pharmaceutical compositions comprising fluvastatin
Abstract: Pharmaceutical compositions comprising fluvastatin, HPMC and optionally other pharmaceutical excipients which are colour-stable upon prolonged periods of storage.
Inventor(s): Kalb; Oskar (Lorrach, DE), Valazza; Stephen (Matawan, NJ)
Assignee: Novartis AG (Basel, CH)
Filing Date:Jul 13, 2010
Application Number:12/835,195
Claims:1. A colour-stable pharmaceutical composition comprising: i) Fluvastatin and hydroxypropyl methyl cellulose, and ii) a coating, wherein said coating comprises 17% to 30% by weight of a colouring agent based on the total weight of the coating.

2. The pharmaceutical composition according to claim 1 in the form of an oral dosage form.

3. The pharmaceutical composition according to claim 1 in the form of granules.

4. The pharmaceutical composition according to claim 3, comprising compressed granules comprising fluvastatin and hydroxypropyl methyl cellulose, wherein said granules have a mean particle size of less than 200 microns.

5. The pharmaceutical composition according to claim 3, wherein the granules comprising fluvastatin and hydroxypropyl methyl cellulose have a mean particle size of less than 200 microns.

6. The pharmaceutical composition according to claim 1 wherein the coating comprises 22 to 25% by weight of a colouring agent based on the total weight of the coating.

7. The pharmaceutical composition according to claim 1 wherein the colouring agent is selected from the group consisting of titanium dioxide and iron oxide.

8. The pharmaceutical composition according to claim 1 wherein the colouring agent is a combination of colouring agents.

9. The pharmaceutical composition according to claim 8, wherein the colouring agent is a combination of titanium dioxide and iron (II) oxide.

10. The pharmaceutical composition according to claim 1, wherein the hydroxypropyl methyl cellulose is present in amounts of from 15 to 50% by weight based on the total weight of the composition.

11. The pharmaceutical composition according to claim 1 additionally comprising a non-ionic hydrophilic polymer is selected from the group consisting of hydroxyethyl cellulose and hydroxypropyl cellulose.

12. The pharmaceutical composition according to claim 11 wherein the ratio of hydroxypropyl methyl cellulose to non-hydrophilic polymer is about 10:1 to 3:11.

13. The pharmaceutical composition according to claim 1 wherein the fluvastatin is fluvastatin sodium.

14. The pharmaceutical composition according to claim 1 where in the pharmaceutical composition is formed of compressed granules.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.